EP0804542A4 - Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same - Google Patents

Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Info

Publication number
EP0804542A4
EP0804542A4 EP95937449A EP95937449A EP0804542A4 EP 0804542 A4 EP0804542 A4 EP 0804542A4 EP 95937449 A EP95937449 A EP 95937449A EP 95937449 A EP95937449 A EP 95937449A EP 0804542 A4 EP0804542 A4 EP 0804542A4
Authority
EP
European Patent Office
Prior art keywords
vaccines
methods
same
enteric bacteria
producing enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95937449A
Other languages
German (de)
French (fr)
Other versions
EP0804542A1 (en
Inventor
John L Pace
Richard I Walker
Steven M Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Antex Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/538,543 external-priority patent/US5681736A/en
Application filed by Antex Biologics Inc filed Critical Antex Biologics Inc
Publication of EP0804542A1 publication Critical patent/EP0804542A1/en
Publication of EP0804542A4 publication Critical patent/EP0804542A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/045—Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP95937449A 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same Withdrawn EP0804542A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US538543 1990-06-15
US31840994A 1994-10-05 1994-10-05
US318409 1994-10-05
US08/538,543 US5681736A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US08/538,545 US5679564A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US538545 1995-10-03
PCT/US1995/013196 WO1996011258A1 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Publications (2)

Publication Number Publication Date
EP0804542A1 EP0804542A1 (en) 1997-11-05
EP0804542A4 true EP0804542A4 (en) 1998-10-28

Family

ID=27405987

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937449A Withdrawn EP0804542A4 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Country Status (16)

Country Link
EP (1) EP0804542A4 (en)
JP (1) JP3394047B2 (en)
CN (1) CN1168693A (en)
AU (1) AU704283B2 (en)
BR (1) BR9509276A (en)
CA (1) CA2202027A1 (en)
CZ (1) CZ104397A3 (en)
FI (1) FI971403A (en)
HU (1) HUT77876A (en)
IL (1) IL115521A0 (en)
MX (1) MX9702431A (en)
NO (1) NO971519L (en)
NZ (1) NZ295907A (en)
PL (1) PL182700B1 (en)
SG (2) SG73509A1 (en)
WO (1) WO1996011258A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ104297A3 (en) * 1994-10-05 1997-11-12 Microcarb Methods of producing higher antigenic heliobacter spp. and vaccines containing thereof
JP2008500007A (en) * 2003-05-30 2008-01-10 インターツェル・アクチェンゲゼルシャフト Enterococcal antigen
US20100074846A1 (en) * 2006-03-17 2010-03-25 Ellis John A Campylobacter Vaccines and Methods of use
US8465754B2 (en) 2007-05-28 2013-06-18 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Bordetella parapertussis whole-cell vaccine composition
CN107513553B (en) * 2017-09-18 2021-05-18 江南大学 Method for screening lactobacillus with antagonistic campylobacter jejuni infection function
CN109633151B (en) * 2018-12-26 2022-03-11 西北农林科技大学 Salmonella enteritidis detection method, test strip and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533492A2 (en) * 1991-09-18 1993-03-24 Amgen Inc. A hepatitis B vaccine formulation incorporating a bile acid salt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533492A2 (en) * 1991-09-18 1993-03-24 Amgen Inc. A hepatitis B vaccine formulation incorporating a bile acid salt

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
95TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, D.C., USA, MAY 21-25, 1995. ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY 95 (0). 1995. 183 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; ROLLINS D M ET AL: "Functional In Vitro Assays for Maximizing Campylobacter Cross-Strain Agglutination Through Optimization of Culture Conditions.", XP002075401 *
POPE L M ET AL: "Increased protein secretion and adherence to HeLa cells by Shigella spp. following growth in the presence of bile salts.", INFECTION AND IMMUNITY, (1995 SEP) 63 (9) 3642-8, XP002075400 *
See also references of WO9611258A1 *

Also Published As

Publication number Publication date
PL319580A1 (en) 1997-08-18
CN1168693A (en) 1997-12-24
SG73510A1 (en) 2000-06-20
AU704283B2 (en) 1999-04-15
NO971519L (en) 1997-05-27
IL115521A0 (en) 1996-06-18
MX9702431A (en) 1998-05-31
NO971519D0 (en) 1997-04-03
NZ295907A (en) 1999-04-29
EP0804542A1 (en) 1997-11-05
CA2202027A1 (en) 1996-04-18
BR9509276A (en) 1997-11-18
JPH10507347A (en) 1998-07-21
CZ104397A3 (en) 1998-06-17
HUT77876A (en) 1998-09-28
JP3394047B2 (en) 2003-04-07
SG73509A1 (en) 2000-06-20
FI971403A0 (en) 1997-04-04
WO1996011258A1 (en) 1996-04-18
FI971403A (en) 1997-06-04
AU3956195A (en) 1996-05-02
PL182700B1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
US5584086B1 (en) Therapeutic pillow and method
HU9602310D0 (en) Urease-based vaccine and treatment for helicobacter infection
EP0555366A4 (en) Bacterial attenuation method and vaccine
EP0769963A4 (en) Polyepitope vaccines
GB9513261D0 (en) Vaccines
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
IL129530A (en) Acellular pertussis vaccine with diphtheria and tetanus-toxoids
GB9410922D0 (en) Vaccines
HUP9701586A3 (en) Improved inactivated vaccines
EP0705673A3 (en) Medical articles and method therefor
IL115521A0 (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
EP0453497A4 (en) Treatment methods and vaccines
PL314303A1 (en) Vaccine designing and producing process
GB9417880D0 (en) Vaccine
GB9416667D0 (en) Vaccines and diagnostics
GB9503867D0 (en) Vaccines and diagnostics
GB9406708D0 (en) Vaccines
GB9320317D0 (en) Vaccines and diagnostics
GB9419969D0 (en) Vaccine
ZA955499B (en) Helicobacter proteins and vaccines
HU9400634D0 (en) Vaccine and diagnosticum against parvovirosis of gooses and barbari duks
ZA952370B (en) Vaccines
GB9405990D0 (en) Vaccines
GB9418058D0 (en) Vaccines
GB9418057D0 (en) Vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 970417

A4 Supplementary search report drawn up and despatched

Effective date: 19980914

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040101